Movatterモバイル変換

Tocilizumab

С Википедије, слободне енциклопедије

Tocilizumab^[1] (INN,atlizumab,Actemra,RoActemra) jeimunosupresivni lek. On se prvenstveno koristi za lečenjereumatoidnog artritisa (RA) i sistemskogjuvenilnog idiopatskog artritisa, teške forme RA kod dece. On jehumanizovano monoklonalno antitelo protivinterleukin-6 receptora (IL-6R).Interleukin 6 (IL-6) jecitokin koji ima važnu ulogu u imunskom odgovoru i koji je impliciran u patogenezi mnogih bolesti, uključujućiautoimune bolesti,multipli mijelom irak prostate.^[2]^[3]^[4]

^Venkiteshwaran, Adith (2009).„Tocilizumab”.MAbs.1 (5): 432—438.PMC 2759492 .PMID 20065633.doi:10.4161/mabs.1.5.9497.
^Mihara M, Nishimoto N, Ohsugi Y: The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody. Expert Opin Biol Ther. 2005 May;5(5):683-90.PMID 15934843
^Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011).„DrugBank 3.0: a comprehensive resource for omics research on drugs”.Nucleic Acids Res.39 (Database issue): D1035—41.PMC 3013709 .PMID 21059682.doi:10.1093/nar/gkq1126. уреди
^David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008).„DrugBank: a knowledgebase for drugs, drug actions and drug targets”.Nucleic acids research.36 (Database issue): D901—6.PMC 2238889 .PMID 18048412.doi:10.1093/nar/gkm958. уреди

Hardman JG, Limbird LE, Gilman AG (2001).Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill.ISBN 0071354697.doi:10.1036/0071422803.
Thomas L. Lemke; David A. Williams, ур. (2007).Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins.ISBN 0781768799.

Intracelularni
(inicijacija)

Antimetaboliti	inhibitor sinteze purinа:Azatioprin • Mikofenolna kiselina/Mikofenolat mofetil inhibitor sinteze pirimidina:Leflunomid • Teriflunomid antifolat:Metotreksat
Makrolidi/ drugiIL-2 inhibitori	FKBP/Ciklofilin/Kalcineurin:Takrolimus • Ciklosporin • Pimekrolimus Abetimus • Gusperimus
TNF-α inhibitor	Talidomid • Lenalidomid

Intracelularni
(recepcija)

Antagonisti IL-1 receptora	Anakinra
mTOR	Sirolimus • Deforolimus • Everolimus • Temsirolimus • Zotarolimus • Biolimus A9

Ekstracelularni

Serum cilj (non-celularni)	Dopunska komponenta 5 (Eculizumab) • TNF (Infliksimab,Adalimumab,Certolizumab pegol,Afelimomab,Golimumab) • Interleukin 5 (Mepolizumab) • Imunoglobulin E (Omalizumab) • BAYX (Nerelimomab) Interferon (Faralimomab) IL-6 (Elsilimomab) IL-12 iIL-13 (Lebrikizumab,Ustekinumab)
Celularni ciljevi	CD3 (Muromonab-CD3,Oteliksizumab,Teplizumab,Visilizumab) • CD4 (Klenoliksimab,Keliksimab,Zanolimumab) • CD11a (Efalizumab) • CD18 (Erlizumab) • CD20 (Afutuzumab,Ocrelizumab,Pascolizumab) • CD23 (Lumiliksimab) • CD40 (Teneliksimab,Toralizumab) • CD62L/L-selektin (Aselizumab) • CD80 (Galiksimab) • CD147/Basigin (Gavilimomab) • CD154 (Ruplizumab) BLyS (Belimumab) • CTLA-4 (Ipilimumab,Tremelimumab) • CAT (Bertilimumab,Lerdelimumab,Metelimumab) • Integrin (Natalizumab) • Interleukin-6 receptor (Tocilizumab) • LFA-1 (Odulimomab) IL-2 receptor/CD25 (Basiliksimab,Daklizumab,Inolimomab) T-limfocit (Zolimomab aritoks)
Nesortirani	Atorolimumab,Cedelizumab,Dorliksizumab,Fontolizumab,Gantenerumab,Gomiliksimab,Maslimomab,Morolimumab,Pekselizumab,Reslizumab,Rovelizumab,Siplizumab,Talizumab,Telimomab aritoks,Vapaliksimab,Vepalimomab